FINWIRES · TerminalLIVE
FINWIRES

Top Midday Gainers

By

Kymera Therapeutics (KYMR) has completed enrollment in its phase 2b Broaden2 trial of KT-621 in moderate-to-severe atopic dermatitis ahead of schedule, the company said Thursday.

Shares jumped 17% following an increase in intraday trading volume to about 2.7 million from a daily average of about 636,000.

WidePoint (WYY) stock surged 14% after the company said it won the Department of Homeland Security's Cellular Wireless Managed Services 3.0 contract.

More than 5.4 million shares of the company traded intraday compared with a daily average of about 140,000.

Bio-Techne (TECH) signed a definitive agreement to be acquired by Merck KGaA for $73 a share, representing an enterprise value of $11.3 billion, the companies said Thursday.

Shares climbed 20% as intraday trading volume catapulted to over 40.7 million from a daily average of about 2.7 million.

Price: $116.86, Change: $+16.99, Percent Change: +17.01%

Related Articles

Wire

Arovella Therapeutics Secures Ethics Approval for First-in-Human Study of Blood Cancer Drug Candidate

Arovella Therapeutics (ASX:ALA) received ethics approval from The Alfred and Bellberry Human Research Ethics Committees to begin its phase 1 first-in-human clinical trial of ALA-101 drug candidate, a chimeric antigen receptor invariant natural killer T (CAR-iNKT) cell therapy for patients with relapsed or refractory lymphomas and leukemias, according to a Thursday Australian bourse filing.The trial is expected to involve up to seven clinical sites across Australia and New Zealand, the filing said. It will evaluate the safety, tolerability, and preliminary anti-tumor activity of ALA-101.The company remains on track to begin first patient dosing in the September quarter.Arovella Therapeutics' shares fell past 1% in recent trading on Thursday and earlier hit their lowest since September 2023.

ASX:ALA
Wire

Update: Tourism Holdings Receives Additional Non-Binding Takeover Offer From Unnamed 'Credible Strategic' Buyer; Shares Over Two-Year High

(Updates to add stock movement in the headline and the last paragraph)Tourism Holdings (ASX:THL, NZE:THL) received an additional non-binding indicative offer from an unnamed "credible strategic" buyer to acquire 100% of the company at a proposed price of NZ$3.30 to NZ$3.40 per share, according to a Thursday filing with the New Zealand and Australian bourses.The proposal is subject to customary conditions, including due diligence, board approval, regulatory and third-party consents, and unanimous board recommendation, subject to standard fiduciary carve-outs, per the filing.The company has allowed the bidder to conduct due diligence under a confidentiality agreement while emphasizing that no decision has been made and there is no assurance that a transaction will proceed, the filing said.The company is also engaged in discussions with the BGH consortium on a similar confidentiality agreement to support due diligence, the filing added.The company's shares on the New Zealand bourse rose 12% in Thursday trading and earlier reached their highest level since April 2024, while Australian shares gained 11%.

ASX:THLNZE:THL
Wire

Lockheed Martin Wins Up to $35 Billion Contract to Expand US Missile Defense Production

Lockheed Martin (LMT) won a seven-year US government contract worth up to $35 billion to quadruple production of its Terminal High Altitude Area Defense interceptors.The award is one of the first major multiyear procurement contracts under the Pentagon's new acquisition strategy, Lockheed Martin said Wednesday in a statement.The contract implements a THAAD framework agreement signed in January and is intended to support long-term production scaling and strengthen the missile-defense industrial base for the US and its allies, the company said.Lockheed Martin shares rose 0.9% in after-hours trading.

$LMT